Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660010 · ClinicalTrials.gov registry record · Phase 3
Study of Lupron Depot In The Treatment of Central Precocious Puberty
A Phase 3 study of Puberty, Precocious, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
- 9
- Study locations
NCT00660010: Completed Phase 3 study of Puberty, Precocious, sponsored by Abbott.
NCT00660010 is a Phase 3 study of Puberty, Precocious that has completed, run by Abbott. The registered enrollment target is 55 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00660010, a Phase 3 study of Puberty, Precocious, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine if Lupron (leuprolide acetate) is safe and effective in treating children with Central Precocious Puberty (CPP), and to assess long term effects of leuprolide acetate treatment after therapy is discontinued.
Primary Outcome
Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of breast development in females. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of breasts. The final visit occurred at a mean age +/- SD of 11.05 +/- 1.14 years (range, 6.96 to 12.95 years).
Conditions Studied
Interventions
- DRUG Lupron (leuprolide acetate)
Study Locations (9)
California
- Site Reference ID/Investigator# 46671 - San Francisco
- Site Reference ID/Investigator# 14921 - Stanford
Arizona
- Site Reference ID/Investigator# 46673 - Phoenix
Colorado
- Site Reference ID/Investigator# 14343 - Aurora
Florida
- Site Reference ID/Investigator# 14341 - St. Petersburg
Indiana
- Site Reference ID/Investigator# 14342 - Indianapolis
Maryland
- Site Reference ID/Investigator# 46672 - Baltimore
Massachusetts
- Site Reference ID/Investigator# 46668 - Springfield
Pennsylvania
- Site Reference ID/Investigator# 14344 - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 1991-01 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
What the finished NCT00660010 record still lists
NCT00660010 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Puberty, Precocious appearing as the primary indexed condition, and to 1 intervention - of which Lupron (leuprolide acetate) is the first listed.
NCT00660010 lists 9 locations in 8 states (California, Arizona, Colorado).
Frequently Asked Questions
What is clinical trial NCT00660010 about?
NCT00660010 is a clinical study titled "Study of Lupron Depot In The Treatment of Central Precocious Puberty". The purpose of this study is to determine if Lupron (leuprolide acetate) is safe and effective in treating children with Central Precocious Puberty (CPP), and to assess long term effects of leuprolide acetate treatment after therapy is discontinued.
What is the current status of trial NCT00660010?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 1991-01. Estimated completion is 2009-04.
What conditions does trial NCT00660010 study?
This clinical trial studies the following conditions: Puberty, Precocious.
What interventions are being tested in trial NCT00660010?
The interventions under investigation include: Lupron (leuprolide acetate) (DRUG).
Who is sponsoring clinical trial NCT00660010?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00660010 being conducted?
This trial has 9 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Puberty, Precocious
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00660010's enrollment target sits among peer trials
55 1834th of 2000 higher than 163 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia